Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metformin
Drug ID BADD_D01401
Description Metformin is an antihyperglycemic agent of the _biguanide_ class, used for the management of type II diabetes) [FDA label]. Currently, metformin is the first drug of choice for the management of type II diabetes and is prescribed to at least 120 million people worldwide [A176173]. Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. Metformin is commonly described as an _insulin sensitizer_ leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels [A176173]. Another well-known benefit of this drug is modest weight loss. Metformin is the drug of choice for obese type II diabetes patients [A36559]. Metformin was first approved in Canada in 1972 [A36552], followed by 1995 in the USA [FDA label]. This drug is available in regular and extended-release forms [FDA label].
Indications and Usage For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM. May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS). Jentadueto is for the treatment of patients when both linagliptin and metformin is appropriate.
Marketing Status Prescription; Discontinued
ATC Code A10BA02
DrugBank ID DB00331
KEGG ID D04966
MeSH ID D008687
PubChem ID 4091
TTD Drug ID D0D7LA
NDC Product Code 0615-8105; 52493-334; 50742-633; 0378-6001; 50742-634; 0378-6002; 60155-001
Synonyms Metformin | Dimethylbiguanidine | Dimethylguanylguanidine | Glucophage | Metformin Hydrochloride | Hydrochloride, Metformin | Metformin HCl | HCl, Metformin
Chemical Information
Molecular Formula C4H11N5
CAS Registry Number 657-24-9
SMILES CN(C)C(=N)N=C(N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin resistanceSolute carrier family 2, facilitated glucose transporter member 1P17809Not Available9802324; 1587399; 8391425
Insulin resistanceSolute carrier family 2, facilitated glucose transporter member 4P14142Not Available9802324; 1587399; 8391425
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.011--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase abnormal13.03.01.0040.000026%Not Available
Aspartate aminotransferase increased13.03.01.0060.000443%
Aspiration22.02.07.0070.000020%
Asterixis17.01.06.001; 09.01.03.0040.000026%Not Available
Asthenia08.01.01.0010.002150%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atelectasis22.01.02.0010.000039%
Atrial fibrillation02.03.03.002--
Atrial flutter02.03.03.003--
Atrial septal defect03.07.02.002; 02.04.02.0090.000248%Not Available
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.000065%
Atrioventricular block first degree02.03.01.004--
Autoimmune hepatitis09.01.07.019; 10.04.09.0010.000169%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000026%Not Available
Azotaemia20.01.01.0010.000182%Not Available
B-cell lymphoma01.15.01.001; 16.28.01.0010.000010%Not Available
Back pain15.03.04.005--
Balanoposthitis21.09.03.0010.000104%Not Available
Benign hydatidiform mole21.07.02.006; 18.05.03.001; 16.04.01.0020.000026%Not Available
Benign prostatic hyperplasia21.04.02.0010.000026%Not Available
Biliary colic09.02.01.0010.000065%Not Available
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Blindness17.17.01.003; 06.02.02.0010.000274%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 42 Pages